Human Complement Receptor 2 / CD21 (CR2) CLIA Kit

Catalogue No.:abx196558

Human CR2 Chemiluminescent Immunoassay (CLIA) Kit is a Chemiluminescent Immunoassay (CLIA) Kit for use with Serum, plasma, tissue homogenates and other biological fluids.

Target:	Complement Receptor 2 / CD21 (CR2)
Reactivity:	Human
Tested Applications:	CLIA
Recommended dilutions:	Optimal dilutions/concentrations should be determined by the end user.
Storage:	Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.
Validity:	The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.
Stability:	The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.
UniProt Primary AC:	P20023 (UniProt, ExPASy)
GeneID:	1380
OMIM:	120650
HGNC:	2336
Ensembl:	ENSG00000117322
Test Range:	78 pg/ml - 5000 pg/ml
Sensitivity:	< 31 pg/ml
Standard Form:	Lyophilized
Detection Method:	Chemiluminescent
Assay Type:	Sandwich

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com

Assay Data:	Quantitative
Sample Type:	Serum, plasma, tissue homogenates and other biological fluids.
Target Type:	Antigen
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES. The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments. Please note that our kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951
Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413
Abbexa BV, Leiden, NL
Website: www.abbexa.com · Email: info@abbexa.com